Perrigo | PRGO - Cash And Equivalent


Perrigo reported $531.6M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Abbott USD 6.8B 1.72B Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Corcept Therapeutics USD 108.74M 11.76M Mar/2026
Dr.Reddys Laboratories INR 18.66B 8.75B Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Nestle CHF 4.58B 73M Dec/2025
Pacira USD 144.31M 14.24M Mar/2026
Perrigo USD 531.6M 99.5M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
Phibro Animal Health USD 54.93M 557K Mar/2026
Prestige Brands USD 63.87M 1.5M Mar/2026
Reckitt Benckiser GBP 880M 106M Dec/2024
Sanofi EUR 7.66B 1.25B Dec/2025
Supernus Pharmaceuticals USD 184.87M 56.42M Mar/2026
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026
Zoetis USD 1.94B 369M Mar/2026